Eiger BioPharmaceuticals (EIGR) Misses Q1 EPS by 10c

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q1 EPS of ($0.52), $0.10 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $4.12 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Pony AI (PONY) Reports Revenue Above Estimates
• Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded